DALLASWith "significant improvement" in both
progression-free and 5-year survival of patients with ovarian cancer,
"quality of life becomes important," stated Alan N. Gordon, MD,
director of research in gynecologic oncology in the Division of Oncology at
Texas Oncology in Dallas.
Addressing an industry-sponsored symposium held in conjunction with the
Oncology Nursing Society annual meeting, Dr. Gordon noted that progress in
the treatment of ovarian cancer in recent years has transformed a formerly
"acute process to one of more chronic disease."
Palliation Becomes Goal
After relapse, palliation becomes the goal, with low toxicity highly
desirable. At present, none of the widely used second-line therapies has yet
been proven decisively superior to the others in survival, he reported.
Pegylated liposomal doxorubicin offers a combination of efficacy and
lower toxicity because the drug’s structure permits it to concentrate in
the tumor and spare normal tissues, he said. In platinum-sensitive patients
it has also shown an "unexpected" increase in overall survival of
4 to 5 months as compared with topotecan (Hycamtin). The etiology of the
"highly significant result" is not clear, he added.
Augmenting Primary Therapy
Integration of taxanes into front-line therapy was a "dominant
research theme of the 1990s," and choosing the platinum compound and
determining dosing and scheduling of the taxane were important issues, Dr.
Gordon continued. Reviewing the results of four studies that explored the
effects of augmenting primary therapy with paclitaxel (Taxol), he noted that
results were "discordant."